{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-23-003720","form_type":"8-K","ticker":"PGEN","cik":"0001356090","company_name":"PRECIGEN, INC.","filed_at":"2023-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.595111+00:00","generated_at":"2026-06-18T11:17:37.187301+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Precigen reports Q4 2022 loss of $22.2M; cash $99.7M; clinical progress in RRP and AML","bullets":["Q4 loss from continuing ops $22.2M ($0.11/sh); full year loss $79.8M ($0.40/sh).","Cash, equivalents, short-term investments, restricted cash $99.7M as of Dec 31, 2022.","Divested Trans Ova Genetics for $162.3M net; retired $156.7M of convertible notes in 2022.","Jan 2023 public offering raised ~$73M net from 44M shares at $1.75/sh.","Positive Phase 1 data: PRGN-2012 in RRP (50% complete response) and PRGN-3006 in AML (27% ORR)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-23-003720","json":"https://secwatch.observer/filing/0000950103-23-003720.json","markdown":"https://secwatch.observer/filing/0000950103-23-003720.md","text":"https://secwatch.observer/filing/0000950103-23-003720.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356090/000095010323003720/0000950103-23-003720-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356090/000095010323003720/dp190237_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T11:17:37.187301+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7d9e27b3d7d3a6cbc4224be14160c6846b33914a","claim":"PRECIGEN, INC. reported financial results for the quarter and year ended December 31, 2022.","evidence_excerpt":"Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated March 6, 2023, reporting its financial results for the quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1356090/000095010323003720/0000950103-23-003720-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}